Risk of acute liver injury associated with the use of drugs: A multicentre population survey

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 12, 2007, Pages 1401-1409

  Sabate M ^a   Ibanez L ^a   Perez E ^a   Vidal, X ^a   Buti, M ^b   Xiol, X ^c   Mas, A ^d   Guarner, C ^e   Forne M ^f   Sola R ^g   Castellote, J ^c   Rigau, J ^h   Laporte, J R ^a  

^a Fundacion Institut Catala de Farmacologia   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f HOSPITAL MÚTUA DE TERRASSA   (Spain)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^h Hospital General   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPRAZOLAM; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CAPTOPRIL; CHLORPROMAZINE; DIAZEPAM; DIPYRONE; ENALAPRIL; ERYTHROMYCIN; FLUOXETINE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; ISONIAZID; LORAZEPAM; METOCLOPRAMIDE; NIMESULIDE; PAROXETINE; PYRAZINAMIDE; RIFAMPICIN; SALBUTAMOL; TICLOPIDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG USE; FEMALE; HEALTH SURVEY; HOSPITAL; HUMAN; INCIDENCE; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POPULATION EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SPAIN;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG TOXICITY; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK;

EID: 34249821036     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03338.x     Document Type: Article

References (39)

1. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002 287 : 2215 20.
2. Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992 232 : 133 8.
3. García Rodríguez LA, Pérez Gutthann S, Walker AM. The role of non-steroidal anti-inflammatory drugs in acute liver injury. BMJ 1992 305 : 865 8.
4. García Rodríguez LA, Ruigomez A, Jick H. A review of epidemiologic research on drug-induced acute liver injury using the General Practice Research Data Base in the United Kingdom. Pharmacoepidemiology 1997 17 : 721 8.
5. de Abajo FJ, Montero D, Madurga M, García Rodríguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004 58 : 71 80.
6. Carson JL, Duff A, Strom BL. Drug-induced acute liver disease. Pharmacoepidemiol Drug Saf 1993 2 : S19 23.
7. Pérez Gutthann S, García Rodríguez LA. The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology 1993 4 : 496 501.
8. Andrade RJ, Lucena MI, Fernandez MC, et al. Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the spanish registry over a 10-year period. Gastroenterology 2005 129 : 512 21.
9. Capellà D, Pedrós C, Vidal X, Laporte JR. Case-population studies in pharmacoepidemiology. Drug Saf 2002 25 : 7 19.
10. Ibáñez L, Pérez E, Vidal X, Laporte JR, GEMHAB. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002 37 : 592 600.
11. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990 11 : 272 6.
12. Ibáñez L, Ballarín E, Vidal X, Laporte J-R. Agranulocytosis associated with calcium dobesilate. Clinical course and risk estimation with de case-control and the case-population approaches. Eur J Clin Pharmacol 2000 56 : 763 7.
13. Wessling A, Boëthius G. Measurement of drug use in a defined population. Evaluation of the defined daily dose (DDD) methodology. Eur J Clin Pharmacol 1990 39 : 207 10.
14. Laporte JR, Ibáñez L, Vidal X, Vendrell L, Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004 27 : 411 20.
15. Anonymous. Droxicam and hepatotoxicity-suspension of marketing authorisations recommended. Who Pharmaceut Newsletter 1995 2 : 1.
16. Anonymous. Withdrawal of medicinal products containing ebrotidine: liver toxicity. WHO Inform Exchange Syst 1998 72 : 1.
17. The European Agency for the Evaluation of Medicinal Products. Committee for propietary medicinal products (CPMP) opinion following an article 31 referral. 2004. CPMP/1724/04. (http://www.emea.eu.int/pdfs/human/referral/ nimesulide/172404en.pdf).
18. Stricker BHCh. Drug-induced hepatic injury, 2nd edn. Amsterdam : Elsevier, 1992.
19. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver, 2nd edn. Philadelphia : Lippincot Williams & Wilkins, 1999.
20. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy. JAMA 1999 281 : 1014 8.
21. García Rodríguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996 156 : 1327 32.
22. Pizarro AE, Andrade RJ, García-Cortés M, Lucena MI, Pérez-Moreno JM, Puertas M. Acute hepatitis due to ticlopidine. A report of 12 cases and review of the literature. Rev Neurol 2001 33 : 1014 20.
23. Zaragoza A, Moreno V, Catalá E. NSAID-induced hepatotoxicity: aceclofenac and diclofenac. Rev Esp Enferm Dig 1995 87 : 472 5.
24. Pérez JM, Puertas M, Fernández A, González MA. Toxic hepatitis caused by aceclofenac. Rev Esp Enferm Dig 1996 88 : 815 6.
25. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily. JAMA 2006 296 : 87 93.
26. Graham GG, Scott KF, Day RO. Tolerability of paracetamol. Drug Saf 2005 28 : 227 40.
27. Prescott LF. Therapeutic misadventure with paracetamol: fact or fiction. Am J Ther 2000 7 : 99 114.
28. Lee W. Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure Hepatology 2004 40 : 6 9.
29. Mas A, Escorsell MA, Fernández J. Insuficiencia hepática aguda Grave. In : Net A, Betbesé AJ, eds. Update en Medicina Intensiva, Barcelona: Ars Medica, 2005 : 343 56
30. García Rodríguez LA, Wallander MA, Stricker BHCh. The risk of acute liver injury associated with cimetidine and other acid-suppressing anti-ulcer drugs. Br J Clin Pharmacol 1997 43 : 183 8.
31. Schwartz MS, Frank MS, Yanoff A, Morecki R. Atenolol-associated cholestasis. Am J Gastroenterol 1989 84 : 1084 6.
32. Yosuf SW, Mishra RM. Hepatic dysfunction associated with atenolol. Lancet 1995 346 : 192.
33. Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002 22 : 169 83.
34. Huerta C, Zhao SZ, García Rodríguez LA. Risk of acute liver injury in patients with diabetes. Pharmacotherapy 2002 22 : 1091 6.
35. Sagir A, Wettsein M, Oette M, Erhardt A, Häussinger D. Budesonide-induced acute hepatitis in an HIV-positive patient with ritonavir as co-medication. AIDS 2002 16 : 1191 2.
36. Capellà D, Bruguera M, Figueras A, Laporte JR. Fluoxetine-induced hepatitis: why is postmarketing surveillance needed? Eur J Clin Pharmacol 1999 55 : 545 6.
37. Inman WHW. Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone. BMJ 1977 1 : 1500 5.
38. Keisu M, Ekman E, Wiholm B-E. Comparing risk estimates of sulphonamide-induced agranulocytosis from the Swedish Drug Monitoring System and a case-control study. Eur J Clin Pharmacol 1992 43 : 211 4.
39. Cheeta S, Schifano F, Oyefeso A, Webb L, Ghodse AH. Antidepressants- related deaths and antidepressant prescriptions in England and Wales, 1998-2000. Br J Psychiatry 2004 184 : 41 7.